ArticleAutophagy2022
MTOR-mediates hepatic lipid metabolism through an autophagic SNARE complex.
Article in Autophagy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 12 citations in OpenAlex.
- Article
- The dual role of mTOR signaling in lung development and adult lung diseases.Cell & bioscience · 2025Review
- A Study on the Protective Impact of Resveratrol on Liver Damage in Rats with Obstructive Jaundice.Combinatorial chemistry & high throughput screening · 2025Article
- ASPP2 deficiency attenuates lipid accumulation through the PPARγ pathway in alcoholic liver injury.Cell biology and toxicology · 2024Article
- mTOR Signaling Pathway and Gut Microbiota in Various Disorders: Mechanisms and Potential Drugs in Pharmacotherapy.International journal of molecular sciences · 2023Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The STX17-SNAP29-VAMP8 SNARE complex mediates autophagosome-lysosome fusion. Our recent study showed that MTOR directly phosphorylates VAMP8's T48 residue in nutrient-rich conditions. Phosphorylated VAMP8 inhibits autophagosome-lysosome fusion by blocking STX17-SNAP29-VAMP8 SNARE complex formation. Our study also showed that SCFD1 is a previously unrecognized macroautophagy/autophagy regulatory protein, which can be recruited by VAMP8 (in its non-phosphorylated form) to autolysosomes, where it promotes STX17-SNAP29-VAMP8 complex assembly - and consequently promotes autophagosome-lysosome fusion. Moreover, we observed that mice harboring a phosphomimic VAMP8 variant accumulate aberrantly high lipid levels in their livers. VAMP8 phosphorylation can disrupt autophagosome-lysosome fusion in the liver and thereby dysregulate lipid metabolism. Beyond providing insights into the molecular mechanisms of autophagosome maturation, our study suggests that modulating autophagic SNARE function may help treat liver lipid disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.